Brief: Tenaya Therapeutics Announces FDA Clearance To Begin Clinical Testing Of TN-401 Gene Therapy
26/10/2023 14:24
Oct 26 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS ANNOUNCES FDA CLEARANCE TO BEGIN
CLINICAL
TESTING OF TN-401 GENE THERAPY FOR THE TREATMENT OF
PKP2-ASSOCIATED ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
Source text for Eikon: ID:nGNX88W9c6
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027